Literature DB >> 11854875

Oxygen consumption after hypothermic cardiopulmonary bypass: the effect of continuing a propofol infusion postoperatively.

Stewart E Milne1, Kenneth S James, Susan Nimmo, Stephen Hickey.   

Abstract

OBJECTIVE: To evaluate the effect of a fixed rate of infusion of propofol on total body oxygen consumption during the postoperative rewarming phase after cardiopulmonary bypass.
DESIGN: Prospective, randomized, controlled study.
SETTING: Cardiac intensive care unit, university hospital. PARTICIPANTS: Twenty-four male and female patients undergoing elective first-time coronary artery bypass graft surgery.
INTERVENTIONS: Total body oxygen consumption was measured using a pulmonary artery catheter and thermodilution during postoperative rewarming. Twelve patients had propofol infused at 2 mg/kg/h for 4 hours or until rewarmed.
MEASUREMENTS AND MAIN RESULTS: Total body oxygen consumption was reduced in the propofol group compared with the control group. Oxygen consumption was a median of 30.0 mL/min/m(2) less in the patients receiving propofol (p = 0.01). One patient receiving propofol shivered compared with 4 in the control group (p = 0.14).
CONCLUSION: Administration of propofol during postoperative rewarming reduces total body oxygen consumption and may reduce shivering. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854875     DOI: 10.1053/jcan.2002.29657

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  2 in total

Review 1.  The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society.

Authors:  Lori Kennedy Madden; Michelle Hill; Teresa L May; Theresa Human; Mary McKenna Guanci; Judith Jacobi; Melissa V Moreda; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

Review 2.  Propofol: a review of its use in intensive care sedation of adults.

Authors:  Kate McKeage; Caroline M Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.